In a statement handed out to reporters, Merck said that the class effect might extend beyond these Cox-2 inhibitors, to many older non-steroidal anti-inflammatory drugs.
These compounds, by virtue of their mode of action, were deemed to be as potent arthritis pain relievers as traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, but were believed to be safer than NSAIDs since they caused less gastrointestinal distress.